Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers - PubMed (original) (raw)
. 1991 Jan 2;83(1):37-42.
doi: 10.1093/jnci/83.1.37.
Affiliations
- PMID: 1984515
- DOI: 10.1093/jnci/83.1.37
Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers
L M Weisenthal et al. J Natl Cancer Inst. 1991.
Abstract
Tumor-specific cytotoxicity was measured in fresh human biopsy specimens by a modification of the differential staining cytotoxicity assay. ImuVert, a cytokine inducer derived from Serratia marcescens, which produces broad-spectrum activation of both macrophages and lymphocytes, was dramatically more effective when it was tested in tumors obtained from patients with previously treated, chemotherapy-responsive adenocarcinomas (breast and ovary) than when it was tested in tumors obtained from either previously untreated patients or previously treated patients with chemotherapy-refractory adenocarcinomas (colon, lung, pancreas, stomach, kidney, gallbladder, uterus, and prostate). Similar findings, relating to prior chemotherapy treatment status, were obtained for tumor necrosis factor and interferon gamma, but not for interleukin-2 or interferon alpha. On the basis of these findings and on other evidence in the literature, we speculate that response to chemotherapy produces massive release and processing of tumor antigens. We further speculate that this response leads to a state in which the human immune system is primed (via in situ vaccination) to respond to exogenous macrophage-activation signals with potent, specific antitumor effects.
Similar articles
- Analysis of chemotherapeutic response heterogeneity and drug clustering based on mechanism of action using an in vitro assay.
Rice SD, Heinzman JM, Brower SL, Ervin PR, Song N, Shen K, Wang D. Rice SD, et al. Anticancer Res. 2010 Jul;30(7):2805-11. Anticancer Res. 2010. PMID: 20683016 - Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR. Varvaresou A, et al. Anticancer Res. 2004 Mar-Apr;24(2B):907-19. Anticancer Res. 2004. PMID: 15161044 - Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH. Kern DH. Cancer J Sci Am. 1998 Jan-Feb;4(1):41-5. Cancer J Sci Am. 1998. PMID: 9467045 - Role of biological response modifiers in immunochemotherapy of solid tumors and retroviral-induced leukemia.
Fuggetta MP, D'Onofrio C, Bonmassar E. Fuggetta MP, et al. Ann Ist Super Sanita. 1990;26(3-4):385-95. Ann Ist Super Sanita. 1990. PMID: 1708953 Review. - Biologic agents as modifiers of chemotherapeutic effects.
Parmiani G, Rivoltini L. Parmiani G, et al. Curr Opin Oncol. 1991 Dec;3(6):1078-86. doi: 10.1097/00001622-199112000-00017. Curr Opin Oncol. 1991. PMID: 1843110 Review.
Cited by
- Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.
Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T, Schmidt-Wolf IG, Mühlradt PF, Schmidt J, Märten A. Schneider C, et al. Gut. 2004 Mar;53(3):355-61. doi: 10.1136/gut.2003.026005. Gut. 2004. PMID: 14960515 Free PMC article. - Pushing the envelope: Immune mechanism and application landscape of macrophage-activating lipopeptide-2.
Liao D, Su X, Wang J, Yu J, Luo H, Tian W, Ye Z, He J. Liao D, et al. Front Immunol. 2023 Jan 24;14:1113715. doi: 10.3389/fimmu.2023.1113715. eCollection 2023. Front Immunol. 2023. PMID: 36761746 Free PMC article. Review. - How to detour Treg cells in T cell-based antitumor immune therapy.
Zheng S, Shen Y, Song Y, Yuan Y. Zheng S, et al. Onco Targets Ther. 2013 Sep 6;6:1243-7. doi: 10.2147/OTT.S48872. eCollection 2013. Onco Targets Ther. 2013. PMID: 24043948 Free PMC article. - Human cell lines as models for multidrug resistance in solid tumours.
Clynes M, Heenan M, Hall K. Clynes M, et al. Cytotechnology. 1993;12(1-3):231-56. doi: 10.1007/BF00744666. Cytotechnology. 1993. PMID: 7765327 Review. - Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.
Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C. Windbichler GH, et al. Br J Cancer. 2000 Mar;82(6):1138-44. doi: 10.1054/bjoc.1999.1053. Br J Cancer. 2000. PMID: 10735496 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources